BOSTON, Sept. 27, 2016 /PRNewswire/ -- DarioHealth Corp. (NASDAQ:DRIO), a leader in digital health and mobile health solutions and the developer of the Dario™ Smart Diabetes Management Solution, today announced the launch of an online store in Canada. This is in collaboration with A&D Medical, a global leader in connected health and biometric measurement devices and services, and Bayshore Specialty Rx Ltd.'s online pharmacy Diabetes Express. 

While Dario is widely accepted under reimbursement in Canada, this partnership with Bayshore Specialty Rx Ltd. allows for a complete online experience for Dario products and supplies. The full service provided by Diabetes Express, a division of Bayshore Specialty Rx Ltd., includes all handling of the prescription and interaction with the insurers. The new online store's URL will be http://mydario.ca and be operated in collaboration with DarioHealth, Diabetes Express and A&D. DarioHealth is responsible for the digital marketing and Diabetes Express will handle reimbursement and the prescription process.

"We are thrilled with these partnership agreements and our launch of a Canadian online store as an implementation of our strategy to make the life of people with diabetes easier," said Erez Raphael, DarioHealth's Chairman and Chief Executive Officer. "Our team at DarioHealth has developed strong direct digital marketing capabilities and combined with our partners' complete end-to-end digital pharmacy capabilities, including prescription processing and reimbursement, we will offer a complete and robust offering to the diabetes population in Canada."

Aleksandra Filipovic, Director of Bayshore Diabetes, stated, "I am confident that the combination of a highly-digital and engaging product like Dario and our online direct to consumer platform will provide an extremely valuable experience for patients with diabetes."

Terry Duesterhoeft, President and CEO of A&D, stated, "Dario is one of the featured products in our Canadian portfolio and we look forward to boosting Dario sales through our digital pharmacy platform."

About A&D Medical

Since 1977, A&D Medical has manufactured and distributed a full line of advanced biometric monitoring solutions including blood pressure monitors, weight scales, activity monitors, and other health monitoring devices for consumer and professional use. A&D Medical is the worldwide leader in connected health and biometric measurement devices and services for consumer wellness and chronic condition management, marketing under the A&D brand globally and also the LifeSource brand in North America. A&D Medical is a division of A&D Company, a global manufacturer of measurement equipment, with operations in Asia, Europe, Australia, Russia, North America, and South America.

For general information about A&D Medical, please visit www.andonline.com.

About Bayshore Specialty Rx Ltd.

A division of Bayshore HealthCare, a premier healthcare provider and a proudly Canadian company since 1966, Bayshore Specialty Rx Ltd., provides a wide-range of patient support programs that include services such as data management support, specialty nursing, specialty pharmacy, reimbursement services and call centre. Bayshore operates more than 45 infusion clinics and pharmacies across the country with the goal to improve patient outcomes through integrated support of complex therapies and community services.

Diabetes Express, A Division of Bayshore Specialty Rx Ltd., is the diabetes focused business unit which works directly with manufacturers, diabetes education clinics and patients to provide the best diabetes product support, access and information within every province in Canada. 

About DarioHealth Corp.

DarioHealth is a leader in digital health self-management solutions. DarioHealth delivers the ability to combine and analyze consumer health data to personalize treatment and advance medical knowledge. The Dario™ Smart Diabetes Management Solution is a platform for diabetes management that combines the Dario Blood Glucose Monitoring System all-in-one blood glucose meter, native smart phone app, website portal and a wide variety of treatment tools to support more proactive and better informed decisions by users living with diabetes, their doctors and healthcare systems.  Having recently launched in the largest market in the world for glucose monitoring, U.S. sales are expected to have a significant impact on revenues and gross margins. With marketing clearance in Europe and the U.S., the Dario iOS mobile app recently launched with reimbursement in the United Kingdom, Australia, Israel, Italy, and Canada, and has also launched in New Zealand, Netherlands, Italy, and Belgium.  For more information, visit http://mydario.investorroom.com/

Cautionary Note Regarding Forward-Looking Statements

This news release and the statements of representatives and partners of DarioHealth Corp. (the "Company") related thereto contain or may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as "plan," "project," "potential," "seek," "may," "will," "expect," "believe," "anticipate," "intend," "could," "estimate" or "continue" are intended to identify forward-looking statements.  For example, when the Company describes the impact on sales and distribution from the new online store, and says that U.S. sales are expected to have a significant impact on the Company's revenues and gross margins, it is using forward-looking statements. Readers are cautioned that certain important factors may affect the Company's actual results and could cause such results to differ materially from any forward-looking statements that may be made in this news release. Factors that may affect the Company's results include, but are not limited to, regulatory approvals, product demand, market acceptance, impact of competitive products and prices, product development, commercialization or technological difficulties, the success or failure of negotiations and trade, legal, social and economic risks, and the risks associated with the adequacy of existing cash resources. Additional factors that could cause or contribute to differences between the Company's actual results and forward-looking statements include, but are not limited to, those risks discussed in the Company's filings with the U.S. Securities and Exchange Commission. Readers are cautioned that actual results (including, without limitation, the timing for and results of the Company's commercial and regulatory plans for Dario™) may differ significantly from those set forth in the forward-looking statements. The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.

DarioHealth Corporate and Media Contact
Shmuel Herschberg
Marketing Director
Shmuel@mydario.com
+1-800-896-9062

DarioHealth Investor Relations Contact
Hayden IR
Rob Fink / Brett Maas
DRIO@HaydenIR.com
+1-646-415-8972 / +1-646-536-7331

Logo - http://photos.prnewswire.com/prnh/20160926/411823LOGO

SOURCE DarioHealth Corp.